Compare LEXX & ACON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEXX | ACON |
|---|---|---|
| Founded | 2004 | 2008 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.7M | 7.4M |
| IPO Year | 2011 | 2022 |
| Metric | LEXX | ACON |
|---|---|---|
| Price | $12.93 | $2.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $1.50 | ★ $7.00 |
| AVG Volume (30 Days) | ★ 70.1K | 61.1K |
| Earning Date | 04-13-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 99.82 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $705,923.00 | $75,730.00 |
| Revenue This Year | N/A | $87.22 |
| Revenue Next Year | $601.47 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 52.05 | ★ 65.62 |
| 52 Week Low | $0.35 | $1.95 |
| 52 Week High | $13.61 | $12.03 |
| Indicator | LEXX | ACON |
|---|---|---|
| Relative Strength Index (RSI) | 72.81 | 41.69 |
| Support Level | $0.62 | $1.95 |
| Resistance Level | $12.89 | $2.50 |
| Average True Range (ATR) | 1.39 | 0.18 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 76.11 | 8.62 |
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain, giving physicians clarity to optimize treatment strategies.